Systemic exposure to immunomodulators after intravenous or subcutaneous administration carries an intrinsic risk related to impaired host defense against infection
Unlike mAb therapeutics, aptamer therapeutics can be formulated for topical administration and very limited systemic exposure
Published precedent demonstrates that dermatologic formulations of oligonucleotides penetrate stratum corneum to reach epidermis and dermis in intact normal human skin at pharmacologically relevant concentrations
Topical application of IL-23 inhibitor aptamer cream (Lenn et al. 2018)
Topical application of ICAM-1 antisense oliogonucleotide cream (Mehta et al. 2000)
Cy3-labeled aptamer (orange) into intact human abdominal skin after 0 (wash control), 6, and 24 hours post dosing.
Uptake of IL-23 aptamer into skin keratinocytes (dashed lines indicating the epidermal junction)
Lenn DJ et al Journal of Investigative Dermatology (2018) 138, 282e290; doi:10.1016/j.jid.2017.07.851
© 2023 Guardian Therapeutics. All rights reserved.
Welcome to the Guardian Therapeutics and Band Therapeutics website. We do not use any cookies or other technologies on this website, except those that are strictly necessary to enable normal functioning of this web page. View our data protection statement.
Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580
General Inquiries:
info@guardian-rx.com
Business Development Inquiries: businessdevelopment@guardian-rx.com